BBOT's Upcoming Presentations at Key Cancer Conference
BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a prominent player in the clinical-stage biopharmaceutical sector, specializing in RAS-pathway malignancies, has exciting news for oncology professionals and researchers. BBOT is poised to showcase significant findings at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This event is set to take place from October 22-26 in Boston, where groundbreaking cancer research will be highlighted.
Poster Presentations to Watch
During the conference, BBOT will present two key poster sessions that promise to provide deep insights into their innovative therapeutic strategies. This event serves as a critical platform for the latest advancements in cancer treatment and highlights BBOT's commitment to tackling formidable challenges in oncology.
First Presentation: BBO-11818
One of the most anticipated presentations is centered around BBO-11818, a novel therapeutic that boasts an orally bioavailable, highly potent, and selective profile as a non-covalent pan-KRAS inhibitor. Preliminary findings show that it exhibits robust anti-tumor activity in preclinical models, particularly those with KRAS mutations. This compelling data will be presented during Poster Session A on October 23, from 12:30 p.m. to 4:00 p.m. ET, by Carlos Stahlhut, PhD, who serves as an Associate Director at BBOT.
Second Presentation: BBO-10203
The second poster, scheduled for Poster Session C on October 25, from 12:30 p.m. to 4:00 p.m. ET, will delve into BBO-10203. This first-in-class agent is a selective breaker of the RAS:PI3K? interaction. It has demonstrated the ability to inhibit tumor growth independently and in tandem with KRAS inhibitors in KRAS mutant models, all while avoiding the common side effect of hyperglycemia. This critical research will be presented by Kerstin Sinkevicius, PhD, Vice President of Pharmacology at BBOT.
BBOT's Commitment to Cancer Research
At the heart of BBOT's mission is the desire to transform treatment paradigms for patients suffering from malignancies driven by RAS and PI3K? oncogenes. These targets are prevalent in a variety of human tumors, making the company’s focus extraordinarily relevant. BBOT aims to provide hope and improved outcomes for patients through its innovative pipeline of small molecule therapeutics.
Stay Connected with BBOT
To explore more about BBOT’s mission and its therapeutic advancements, individuals can visit their official website. Moreover, BBOT encourages professionals and interested parties to engage with the company on their LinkedIn platform to stay updated on their latest news and developments.
Frequently Asked Questions
What is the AACR-NCI-EORTC International Conference?
The AACR-NCI-EORTC International Conference is a leading event that focuses on recent advancements in molecular targets and their therapeutic applications in cancer treatments.
What therapies will BBOT present during the conference?
BBOT will present BBO-11818 and BBO-10203, both of which are novel therapeutics aimed at KRAS and RAS/PI3K? interactions, respectively.
Who are the presenters for BBOT's research?
Carlos Stahlhut, PhD, will present BBO-11818 and Kerstin Sinkevicius, PhD, will present BBO-10203 during their respective poster sessions.
How does BBOT's research contribute to cancer treatment?
BBOT's research targets crucial oncogenes responsible for many cancers, developing therapies that may improve clinical outcomes for patients.
Where can I find more information about BBOT?
For more details, visit www.bbotx.com or follow these developments on their LinkedIn page.
